MiNK Therapeutics, Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.60 | $-0.62 | -3.3% | Miss |
| Q12026 FY2026 | $-0.77 | $-0.57 | +26.0% | Beat |
| Q42025 FY2025 | $-0.68 | $-0.56 | +17.6% | Beat |
Back to INKT overview · INKT holders · INKT KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.